Is it a good company at a reasonable price? This stock is rather risky as they are not making a profit and Revenue is declining. Analysts expect a turn around in Revenue this year. This is a small cap so that makes it risky also. I am currently going to hold on to my shares to see how this all works out. I do not have much invested. It is hard to know if the taking a risk on this stock will work out to have a reward. This stock price is cheap, but being cheap does not necessarily make it a good buy.
I own this stock of HLS Therapeutics Inc (TSX-HLS, OTC-HLTRF). I got this stock because it did a reverse takeover of Automodular Corp (TSX-AM, OTC-AMZKF) on March 12, 2018. There was a plan of arrangement whereby Automodular shareholders got 0.165834 HLS common shares and one HLS preferred share. The HLS preferred shares were a form of contingent value right allowing AMD shareholders to have an equity stake linked to the outcome of litigation that had been ongoing for several years between AMD and General Motors. I bought some stock in 2018, 2020 and 2023 because this is a Health Care sector stock and there are few of them in the Canadian market.
When I was updating my spreadsheet, I noticed I have not made money on this stock. My Total Return was a 16.34% loss with a 17.43% from capital loss and 1.09% from dividends. The main problem is that the company is not making a profit. Analysts do not expect the company to make a profit until 2028.
If you had invested in this company in December 2015, for $1,003.32 you would have bought 26 shares at $10.24 per share. In December 2025, after 10 years you would have received $93.10 in dividends. The stock would be worth $472.36. Your total return would have been $565.46. This would be a total loss of 7.06% per year with 8.30% from capital loss and 1.24% from dividends.
| Cost | Tot. Cost | Shares | Years | Dividends | Stock Val | Tot Ret |
|---|---|---|---|---|---|---|
| $10.24 | $1,003.32 | 98 | 9 | $93.10 | $472.36 | $565.46 |
This stock no longer buys a dividend, so there are no current dividend yield and Dividend Payout Ratios (DPR).
Debt Ratios are fine. The Long Term Debt/Market Cap Ratio for 2025 is good at 0.44 and currently at 0.40. The Liquidity Ratio for 2025 is low at 1.11 and too low at 1.00 currently. If you added in Cash Flow after dividends, the ratios are fine at 1.77 and currently at 1.70. The Debt Ratio for 2025 is good at 1.81 and 1.81 currently. The Leverage and Debt/Equity Ratios for 2025 are fine at 2.23 and 1.23 and currently at 2.24 and 1.24.
| Type | Year End | Ratio Curr |
|---|---|---|
| Lg Term | 0.44 | 0.40 |
| Intang/GW | 0.98 | 0.98 |
| Liquidity | 1.11 | 1.00 |
| Liq. + CF | 1.77 | 1.70 |
| Debt Ratio | 1.81 | 1.81 |
| Leverage | 2.23 | 2.24 |
| D/E Ratio | 1.23 | 1.24 |
The Total Return per year is shown below for years of 5 to 10 to the end of 2025 in CDN$. Under the Capital Gain column is the portion of the Total Return attributable to capital gains. Under the Dividend column is the portion of the Total Return attributable to dividends. See chart below.
| From | Years | Div. Gth | Tot Ret | Cap Gain | Div. |
|---|---|---|---|---|---|
| 2020 | 5 | 0.00% | -22.46% | -23.17% | 0.71% |
| 2015 | 10 | -7.06% | -8.30% | 1.24% |
The Total Return per year is shown below for years of 5 to 10 to the end of 2025 in US$. Under the Capital Gain column is the portion of the Total Return attributable to capital gains. Under the Dividend column is the portion of the Total Return attributable to dividends. See chart below.
| From | Years | Div. Gth | Tot Ret | Cap Gain | Div. |
|---|---|---|---|---|---|
| 2020 | 5 | 0.00% | -23.64% | -24.35% | 0.71% |
| 2015 | 10 | -7.01% | -8.49% | 1.48% |
The 5-year low, median, and high median Price/Earnings per Share Ratios are negative and useless. The corresponding 10 year ratios are negative and useless. The corresponding Historical ratios are negative and useless. The current ratios are negative and so useless. I can do no testing on this item. A positive EPS is expected in 2028 with a P/E Ratio of 46.35, a rather high ratio.
I cannot do any Price/Graham Price testing because of all the earnings losses.
I get a 10-year median Price/Book Value per Share Ratio of 1.72. The current ratio is 1.74 based on a Book Value of $58.6M, Book Value per Share of $1.87 and a stock price of $3.24. The current ratio is 0.9% above the 10 year median ratio. This stock price testing suggests that the stock price is relatively reasonable and at the median. This testing is in US$
I get a 10-year median Price/Cash Flow per Share Ratio of 11.38. The current ratio is 5.11 based on a stock price $3.24, Cash Flow for the last 12 months of $19.95M, and Cash Flow per Share of $0.64. The current ratio is 55% below the 10 year median ratio. This stock price testing suggests that the stock price is relatively cheap. This testing is in US$.
I cannot do any dividend yield testing as this company is currently not paying any dividend.
The 10-year median Price/Sales (Revenue) Ratio is 4.12. The current ratio is 1.76 based on Revenue estimate for 2025 of $58M, Revenue per Share of $1.85 and a stock price of $3.24. The current ratio is 57% below the 10 year median ratio. This stock price testing suggests that the stock price is relatively cheap.
Results of stock price testing is that the stock price is probably cheap. The P/S Ratio test is a good one and says that the stock price is relatively cheap. The other two tests I could do said that it was either cheap or reasonable and at the median.
When I look at analysts’ recommendations, I find Strong Buy (1), Buy (1) and Hold (2). The consensus is a Buy. The 12 month stock price consensus is $7.15 ($5.18 US$) with a high of $12.06 ($8.73 US$) and low of $4.52 ($3.27 US$). The consensus stock price of $7.15 implies a total return of 59.67% all from capital gains.
There are no entries for this stock on Stock Chase. Adam Othman on Motley Fool talked about this stock in 2023. He says that this stock will give you exposure to the pharmaceutical industry. The other stock he mentions of Knight Therapeutics (TSX-GUD) is at least currently recovering. The company put out a press release via Newswire about their annual results for 2025. The company put out a press release via Newswire about their first quarter of 2026 results.
Simply Wall Street via Yahoo Finance recently reviewed this stock. They talk about analyst expecting the company to be profitable in 2028. However, they think it might happen later than that unless the company grows aggressively. Simply Wall Street report has a problem with the level of debt this company has. Simply Wall Street site does not list any risks on this stock. It seems that Simply Wall Street is the only place I can find any recent valuations of this stock. It is not on Stock Chase and reviews on Motley Fool are old.
Simply Wall Street via Yahoo Finance reviewed this stock in January 2025. They talk about the decline in the stock and the fact that HLS has only slow revenue growth and is not making a profit.
When I asked google why this company has fallen, because its stock is why down, it said HLS Therapeutics Inc. (TSX: HLS) has experienced a long-term decline in its stock price primarily due to ongoing unprofitability, persistent revenue headwinds, and a historically high debt-to-equity ratio. It referenced Simply Wall Street. They are right.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada. Its web site is here HLS Therapeutics Inc.
The last stock I wrote about was about was Pizza Pizza Royalty Corp (TSX-PZA, OTC-PZRIF) ... learn more. The next stock I will write about will be Reitmans (Canada) Ltd (TSXV-RET.A, OTC-RTMAF) ... learn more on Wednesday, June 10, 2026 around 5 pm. Tomorrow on my other blog I will write about Canadian Women Regret About Money.... learn more on Tuesday, June 9, 2026 around 5 pm.
This blog is meant for educational purposes only and is not to provide investment advice. I am not a licensed professional investment advisor. Before making any investment decision, you should always do your own research or consult an investment professional. I do research for my own edification and I am willing to share. I write what I think and I may or may not be correct.
See my site for an index to these blog entries and for stocks followed. I have three blogs. The first talks only about specific stocks and is called Investment Talk. The second one contains information on mostly investing and is called Investing Economics Mostly. My last blog is for my book reviews and it is called Non-Fiction Mostly. Follow me on Twitter. I am on Instagram. Or you can just Google #walktoronto spbrunner8166 to see my pictures.
Also, on my book blog I have put a review of the book The Ancient Near East by Amanda Podany learn more...